Gastric acid suppressants and cognitive decline in people with or without cognitive impairment

Che-Yuan Wu1,2 | Lisa Y. Xiong1,2 | Michael Ouk2 | Jennifer S. Rabin2,3,4,5 | Nathan Herrmann6,7 | Krista L. Lanctôt1,2,7,8 | Moira K. Kapral9,10,11 | Marcus Law12,13 | Hugo Cogo-Moreira2,14 | Jodi D. Edwards15,16,17 | Walter Swardfager1,2,8,18

1 Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
2 Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada
3 Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, Ontario, Canada
4 Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
5 Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada
6 Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
7 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
8 KITE University Health Network Toronto Rehabilitation Institute, Toronto, Ontario, Canada
9 ICES, Toronto, Ontario, Canada
10 Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
11 Division of General Internal Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
12 University Health Network Toronto Rehabilitation Institute, Toronto, Ontario, Canada
13 Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
14 Faculty of Education, ICT, and Learning, Østfold University College, Halden, Norway
15 University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada
16 School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
17 ICES, Ottawa, Ontario, Canada
18 Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada

Correspondence
Walter Swardfager, Department of Pharmacology and Toxicology, University of Toronto, 1 King’s College Circle, Toronto, Ontario, MSS 1A8, Canada.
Email: w.swardfager@utoronto.ca

Abstract
Introduction: Studies suggest associations between proton pump inhibitors (PPIs) and dementia risk; however, many neither considered histamine-2 receptor antagonists (H2RAs) nor baseline cognitive status.

Methods: Participants (National Alzheimer’s Coordinating Center Database; 2005–2021) using a PPI or H2RA were compared. Covariate-adjusted Cox regression was used to estimate hazard ratios (HR) for progression from normal cognition to mild cognitive impairment (MCI), and from MCI to dementia over 5 years. In a propensity-score–matched subsample of mild–moderate Alzheimer’s disease (AD),
mixed-effects negative binomial regression was used to estimate decline in delayed recall memory.

**Results:** Compared to PPI, H2RA use was associated with earlier progression from MCI to dementia (HR = 1.40 [1.09–1.81]; n = 1701), and with faster memory decline in AD over time (rate ratio = 0.76 [0.64–0.92]; n = 628), but not with progression from normal cognition to MCI (HR = 0.94 [0.71–1.24]; n = 2784).

**Discussion:** Compared to PPIs, H2RAs were associated with cognitive decline, specifically among people with pre-existing cognitive impairment.

**KEYWORDS**
Alzheimer’s disease, cognition, dementia, gastric acid suppressant, histamine-2 receptor antagonist, memory, mild cognitive impairment, proton pump inhibitor

**INTRODUCTION**
Proton pump inhibitors (PPIs) are gastric acid suppressants and one of the most commonly used medications worldwide. Several observational studies have suggested that PPI use is associated with a higher risk of dementia compared to no use; however, many of those studies did not consider the use of histamine-2 receptor antagonists (H2RAs), the other class of acid suppressants used for similar indications. Thus, it is unclear whether the previous estimates of dementia risk are due to the drug indication or to the drug itself. Furthermore, increasing evidence suggests that use of H2RAs is associated with greater risks of dementia and cognitive decline compared to no use, although those findings have been inconsistent. Clinically, physicians or patients may be confronted with choosing either a PPI or an H2RA when potent gastric acid suppression is necessary; therefore, it is important to determine whether one class is associated with a slower rate of cognitive decline compared to the other. Because few studies have specifically compared PPI versus H2RA monotherapy, with mixed evidence, the present study investigates whether there is a difference in cognitive decline between H2RA versus PPI monotherapy users.

The majority of studies examining acid suppressant use and cognitive decline have focused on incident dementia. Few studies have examined the association between cognitive decline and PPI versus H2RA use in people with pre-existing cognitive impairment who may be particularly vulnerable to their adverse (e.g., anticholinergic) effects. Therefore, the present study examines longitudinal associations between H2RA versus PPI use and cognitive decline in a large sample stratified by baseline cognitive status, to determine specifically whether the evidence suggests that a particular acid suppressant may be more detrimental to cognition and whether the association may differ by baseline cognitive status. We hypothesized that H2RA use would be associated with greater cognitive decline over time compared to PPI use, specifically in people with cognitive impairment. Because acid suppressants are some of the most commonly used drugs, evidence of differential risks between the classes would help to optimize pharmacotherapy for many older people requiring an acid suppressant, with potential for broad public health implications.

**METHODS**

**2.1 Data source**

The National Alzheimer’s Coordinating Center (NACC) was established in 1999, and is comprised of case-series data from approximately 42 Alzheimer’s Disease Research Centers (ADRCs) funded by National Institute on Aging (NIA) across the United States. Data are collected in a standardized manner from different ADRCs to form the Uniform Data Set (UDS), as described previously. The UDS was implemented in September 2005, and the dataset is still expanding. The ADRCs enroll participants through referral by clinicians, family members, or patients themselves, and through active recruitment from community organizations. Written informed consent was obtained from all participants and co-participants (usually a close friend or family member). Participants were followed up for UDS visits approximately annually, and the UDS data collection forms were completed by clinicians.

**2.2 Sample selection**

Participants using an H2RA or PPI were selected. People with cancer or on chemotherapy were excluded from the study. Analyses were performed separately in people with clinically diagnosed mild–moderate Alzheimer’s disease (AD), mild cognitive impairment (MCI), and normal cognition. Prevaling clinical diagnostic criteria and the Clinical Dementia Rating (CDR® Dementia Staging Instrument) were used to classify participants into each study group.

Participants who had a global CDR score of 1 or 2 and met NIA and Alzheimer’s Association (NIA-AA) or National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease...
and Related Disorders Association criteria were included in the group of clinically diagnosed mild–moderate AD. Participants who had a global CDR score of 0.5 and met the Petersen’s criteria were included in the MCI group. Normal cognitive status was based on clinician judgment, and all participants included in the normal cognition group had a global CDR score of 0. Cognitively normal participants on a drug for dementia (i.e., cholinesterase inhibitors or memantine) at baseline were excluded. Within each study group, CDR Sum of Boxes (CDR-SOB) was further used to mitigate potential misclassification bias. Cognitively normal individuals who had CDR-SOB > 0.5 at baseline, those with MCI who had CDR-SOB > 4 at baseline, and those with mild–moderate AD who had CDR-SOB > 15 at baseline were excluded.

2.3 | Drug exposure

Medication use at each visit was collected using a structured medication inventory. Participants or co-participants were asked to bring to the study visit or report medications used currently or within the past 2 weeks, and the medication form was completed by trained ADRC staff physicians. All prescription medications were required to be reported, but it was optional to report over-the-counter drugs.

Participants who reported using an H2RA or PPI at the baseline of the analysis were classified as an H2RA or PPI user, respectively, but those using both an H2RA and a PPI at the baseline of the analysis were excluded. Data after a switch from an H2RA to a PPI (and vice versa) were censored to avoid risk factor misattribution. Data beyond discontinued use of H2RAs or PPIs were not censored, as there might be carry-over effects of drug exposure or a lag in cognitive decline.

2.4 | Cognitive outcomes

In normal cognition, the primary outcome was time to MCI or all-cause dementia (if dementia was diagnosed without a preceding MCI diagnosis). In MCI, the primary outcome was time to all-cause dementia. Identification of MCI or dementia was made by clinician judgment at every UDS visit. MCI diagnosis was based on Petersen’s criteria. Participants were considered to meet dementia criteria when they exhibited symptoms that interfered with daily functioning, exhibited functional decline, had low performance on cognitive assessments, showed impairment in at least one cognitive domain, and cognitive decline could not be explained by a major psychiatric disorder or delirium, and/or when they fulfilled other established clinical criteria for dementia, as described in the NACC database.

To explore a sensitive and specific cognitive domain related to AD, delayed recall memory was examined in people with normal cognition, MCI, and mild–moderate AD. Delayed recall memory performance was assessed using the Wechsler Memory Scale Revised—Logical Memory test IIA (score range from 0 to 25; better scores indicate better performance in episodic memory).

A follow-up window over 5 years from baseline plus a 6-month censoring interval (i.e., 5.5 years to capture most 5-year visits) was applied to all the outcomes to infer the associations between baseline drug use and cognition with more confidence while also considering the possible carry-over effects of drugs.

2.5 | Statistical analysis

All analyses were conducted using R 4.0.5, and the figures were created using the graphics or ggplot2 packages.

Cox proportional hazards regression models were used to assess whether baseline use of H2RA versus PPI was associated with differential conversion from normal cognition to cognitive impairment due to MCI or dementia, and differential conversion from MCI to dementia over 5 years (survival package). To address potential confounders, the hazard ratios (HRs) were adjusted for baseline covariates, including age, sex, CDR-SOB as a general functional measure for cognitive impairment, ethnicity (White vs. not White), years of education, body mass index, apolipoprotein E (APOE) ε4 genotype, vitamin B12 deficiency, diabetes, hypertension, hyperlipidemia, depression, cardiovascular disease, history of stroke or transient ischemic attack (TIA), polypharmacy (> 7 drugs reported), active or recent smoking status, alcohol abuse, and reported use of antacids, multivitamins, anti-inflammatory agents, anti-coagulants, and medications for dementia. The proportional hazards assumption was inspected using scaled Schoenfeld residuals. An independent variable was considered to violate the assumption when the scaled Schoenfeld residuals did not fit a straight horizontal line over time.
For analyses of memory performance, participants with available baseline covariates and delayed recall memory scores at any visit were included. Within normal controls, MCI, and mild–moderate AD groups, H2RA users were matched to PPI users by propensity score (MatchIt package) using the greedy nearest neighbor matching method with a ratio of 1:3.38 The abovementioned baseline covariates were included in the propensity score calculation as potential confounders, and a standardized difference < 0.1 was considered balanced. As the delayed recall memory score is a count variable, a random-intercept mixed-effects negative binomial regression model controlling for concurrent use of dementia medication at each visit was used to assess baseline use of an H2RA versus PPI in rates of change in delayed recall memory over 5 years (lme4 package).39 A mixed-effects Poisson regression model was chosen when the data could not fit a negative binomial regression owing to no overdispersion. The longitudinal association was assessed by a drug × time interaction term in the model, and the effect size was expressed as a rate ratio (RR), indicating the fold-change in score over time. An RR smaller than 1 indicated faster decline in the non-reference level.

3 | RESULTS
3.1 | Participant characteristics

Of 43,746 participants from September 2005 to February 2021, a total of 11,605 participants were identified to have used an H2RA and/or PPI. Details of the selection process are shown in Figure 1. A total of 1701 people with MCI and 2784 people with normal cognition met the inclusion criteria and were included in the analyses for the progression to cognitive impairment or dementia. Baseline characteristics of H2RA and PPI users with normal cognition or MCI that were included in the analyses are shown in Table 1. The memory analyses consisted of 628, 820, and 1520 people with mild–moderate AD, MCI, and normal cognition, respectively.

Among participants included in all analyses, there were no users of anticholinergic agents for ulcer treatment (pirenzepine, propantheline, or oxyphenonium).
#### TABLE 1  Baseline subject characteristics for normal cognition and MCI

|                      | Normal cognition | Mild cognitive impairment |
|----------------------|------------------|--------------------------|
|                      | H2RA users (n = 547) | PPI users (n = 2237) | H2RA users (n = 288) | PPI users (n = 1413) |
| Age                  | 73.11 (9.69)     | 73 (9.35)               | 76.22 (9.61)       | 75.7 (9.11)          |
| Female               | 67% (364)        | 66% (1477)              | 55% (158)          | 52% (734)           |
| White                | 81% (445)        | 83% (1846)              | 78% (226)          | 83% (1173)          |
| Years of education   | 15.45 (3.01)     | 15.53 (3.01)            | 14.91 (3.5)       | 15.06 (3.39)        |
| Body mass index      | 27.91 (5.40)     | 28.54 (5.45)            | 27.95 (5.78)      | 27.71 (5.12)        |
| APOE*4 carriers      | 30% (166)        | 28% (632)               | 39% (112)          | 40% (559)           |
| Vitamin B12 deficiency | 4% (24)     | 5% (114)               | 10% (28)          | 8% (108)            |
| Diabetes             | 16% (85)         | 16% (350)               | 19% (56)          | 20% (281)           |
| Hypertension         | 56% (307)        | 62% (1384)              | 64% (183)         | 65% (920)           |
| Hyperlipidemia       | 58% (319)        | 61% (1369)              | 58% (167)         | 67% (944)           |
| Depression           | 10% (57)         | 12% (265)               | 25% (73)          | 27% (375)           |
| Cardiovascular disease | 25% (137)    | 24% (532)               | 28% (80)          | 30% (427)           |
| Stroke or TIA history | 11% (58)       | 8% (169)                | 14% (39)          | 15% (211)           |
| Polypharmacy (> 7 drugs) | 52% (287)    | 52% (1158)              | 56% (161)         | 60% (844)           |
| Antacid use          | 13% (71)         | 9% (204)                | 7% (20)           | 10% (138)          |
| Multivitamin use     | 42% (230)        | 42% (934)               | 33% (94)          | 40% (562)           |
| Anti-inflammatory use | 53% (290)       | 50% (1109)              | 49% (142)         | 52% (728)           |
| AD medication        | –                | –                       | 22% (62)          | 23% (322)          |
| Alcohol abuse        | 4% (20)          | 4% (90)                 | 6% (17)           | 7% (95)            |
| Recent or active smoking | 43% (234) | 47% (1051)              | 49% (141)         | 46% (652)          |
| Anti-coagulant use   | 47% (259)        | 44% (974)               | 52% (150)         | 51% (721)          |
| CDR SOB              |                  |                         |                  |                    |
| CDR SOB = 0.5 versus. = 0 | 5% (25)     | 4% (79)                 | –                 | –                  |
| CDR SOB              |                  |                         | 1.42 (0.92)       | 1.32 (0.89)        |
| H2RA                 |                  |                         |                  |                    |
| Cimetidine           | 3% (15)          | –                       | 2% (5)            | –                  |
| Famotidine           | 30% (162)        | –                       | 35% (100)         | –                  |
| Nizatidine           | 1% (7)           | –                       | <1% (1)           | –                  |
| Ranitidine           | 67% (364)        | –                       | 64% (183)         | –                  |
| PPI                  |                  |                         |                  |                    |
| Dexlansoprazole      | –                | 1% (23)                 | –                 | 1% (15)            |
| Esomeprazole         | –                | 15% (330)               | –                 | 15% (214)          |
| Lansoprazole         | –                | 8% (179)                | –                 | 9% (121)           |
| Pantoprazole         | –                | 15% (328)               | –                 | 16% (225)          |
| Omeprazole           | –                | 59% (1322)              | –                 | 56% (795)          |
| Rabeprazole          | –                | 4% (81)                 | –                 | 4% (52)            |

Note: Categorical variables were reported in proportion (frequency), and continuous variables were reported in mean (standard deviation). Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CDR SOB, Clinical Dementia Rating Sum of Boxes; H2RA, histamine-2 receptor antagonist; MCI, mild cognitive impairment; PPI, proton pump inhibitor; TIA, transient ischemic attack.
|                  | Normal cognition (n = 380) | Matched PPI users (n = 1140) | P-value | Std. Dif. | Mild cognitive impairment (n = 205) | Matched PPI users (n = 615) | P-value | Std. Dif. | Mild-to-moderate AD (n = 157) | Matched PPI users (n = 471) | P-value | Std. Dif. |
|------------------|---------------------------|-------------------------------|---------|-----------|------------------------------------|-------------------------------|---------|-----------|-------------------------------|-------------------------------|---------|-----------|
| Age              | 74.64 (9.57)              | 74.22 (9.31)                  | .440    | 0.045     | 76.78 (9.54)                       | 76.66 (9.04)                  | .869    | 0.013     | 77.27 (9.6)                   | 77.62 (8.77)                  | .672    | 0.038     |
| Female           | 65% (248)                 | 65% (738)                     | .852    | 0.011     | 54% (110)                          | 56% (346)                     | .516    | 0.052     | 57% (89)                      | 57% (268)                     | .963    | 0.004     |
| Whites           | 83% (314)                 | 83% (942)                     | >.999   | 0.000     | 75% (154)                          | 75% (464)                     | .925    | 0.008     | 77% (121)                     | 80% (376)                     | .513    | 0.057     |
| Years of education | 15.19 (3.18)            | 15.23 (3.1)                   | .835    | 0.012     | 14.54 (3.77)                       | 14.56 (3.37)                  | .940    | 0.006     | 13.54 (4.7)                    | 13.78 (3.7)                    | .919    | 0.009     |
| Body mass index  | 27.84 (5.35)              | 28.01 (5.41)                  | .588    | 0.032     | 28.08 (5.72)                       | 28.08 (5.65)                  | .992    | 0.001     | 26.94 (4.89)                   | 26.99 (5.08)                   | .746    | 0.030     |
| APOE*4 carriers  | 28% (108)                 | 28% (324)                     | >.999   | 0.000     | 39% (80)                           | 41% (254)                     | .566    | 0.046     | 57% (89)                      | 55% (257)                     | .606    | 0.047     |
| Vitamin B12 deficiency | 5% (20)              | 5% (58)                       | .893    | 0.008     | 10% (20)                           | 8% (51)                       | .519    | 0.051     | 8% (13)                       | 9% (43)                       | .668    | 0.040     |
| Diabetes         | 16% (60)                  | 15% (166)                     | .560    | 0.034     | 20% (42)                           | 20% (121)                     | .801    | 0.02      | 22% (34)                      | 20% (93)                      | .712    | 0.034     |
| Hypertension     | 62% (236)                 | 62% (704)                     | .903    | 0.007     | 68% (139)                          | 67% (412)                     | .830    | 0.017     | 73% (115)                     | 74% (349)                     | .834    | 0.019     |
| Hyperlipidemia   | 62% (235)                 | 62% (708)                     | .927    | 0.005     | 60% (122)                          | 60% (371)                     | .837    | 0.017     | 63% (99)                      | 64% (300)                     | .886    | 0.013     |
| Depression       | 10% (37)                  | 9% (102)                      | .644    | 0.027     | 26% (54)                           | 26% (160)                     | .927    | 0.007     | 34% (54)                      | 34% (161)                     | .961    | 0.004     |
| Cardiovascular disease | 27% (103)           | 26% (296)                     | .662    | 0.026     | 32% (65)                           | 31% (193)                     | .931    | 0.007     | 24% (37)                      | 25% (120)                     | .915    | 0.01      |
| Stroke or TIA history | 13% (51)              | 12% (141)                     | .593    | 0.031     | 17% (34)                           | 16% (98)                      | .826    | 0.018     | 14% (22)                      | 15% (71)                      | .713    | 0.034     |
| Polypharmacy (> 7 drugs) | 50% (189)          | 49% (559)                     | .813    | 0.014     | 55% (112)                          | 55% (336)                     | >.999   | 0.000     | 63% (99)                      | 66% (313)                     | .643    | 0.043     |
| Antacid use      | 12% (44)                  | 11% (129)                     | .889    | 0.008     | 8% (17)                            | 9% (58)                       | .624    | 0.04      | 10% (16)                      | 11% (53)                      | .461    | 0.067     |
| Multivitamin use | 40% (151)                 | 40% (452)                     | .976    | 0.002     | 30% (61)                           | 33% (204)                     | .365    | 0.074     | 36% (56)                      | 38% (177)                     | .632    | 0.044     |
| Anti-inflammatory use | 52% (197)           | 53% (603)                     | .722    | 0.021     | 49% (101)                          | 50% (307)                     | .872    | 0.013     | 48% (76)                      | 50% (236)                     | .746    | 0.03      |
| Dementia medication | -                     | -                              | -       | -         | 20% (42)                           | 22% (137)                     | .591    | 0.044     | 71% (111)                     | 71% (335)                     | .692    | 0.036     |
| Alcohol abuse    | 4% (14)                   | 4% (44)                       | .877    | 0.009     | 7% (14)                            | 8% (49)                       | .596    | 0.043     | 6% (10)                       | 6% (26)                       | .674    | 0.039     |
| Recent or active smoking | 47% (177)          | 47% (534)                     | .929    | 0.005     | 51% (105)                          | 53% (325)                     | .686    | 0.033     | 40% (63)                      | 42% (198)                     | .438    | 0.071     |
| Anti-coagulant use | 48% (184)             | 49% (553)                     | .976    | 0.002     | 54% (111)                          | 53% (329)                     | .872    | 0.013     | 49% (77)                      | 51% (241)                     | .925    | 0.009     |

(Continues)
|                  | Normal cognition | Mild cognitive impairment | Mild-to-moderate AD |
|------------------|------------------|--------------------------|---------------------|
|                  | H2RA users (n = 380) | Matched PPI users (n = 1140) | P-value | Std. Dif. | H2RA users (n = 205) | Matched PPI users (n = 615) | P-value | Std. Dif. | H2RA users (n = 157) | Matched PPI users (n = 471) | P-value | Std. Dif. |
| CDR SOB          |                  |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| CDR SOB = 0.5 versus = 0 | 6% (22) | 5% (56) | .502 | 0.039 |                  |                          |         |          |                  |                          |         |          |
| CDR SOB          |                  |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| H2RA             |                  |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| Cimetidine       | 4% (14)          |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| Famotidine       | 28% (105)        |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| Nizatidine       | 2% (7)           |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| Ranitidine       | 67% (255)        |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| PPI              |                  |                          |         |          |                  |                          |         |          |                  |                          |         |          |
| Dexlansoprazole  | –                | 1% (10)                  |         |          |                  |                          |         |          |                  |                          |         |          |
| Esomeprazole     | –                | 15% (174)                |         |          |                  |                          |         |          |                  |                          |         |          |
| Lansoprazole     | –                | 10% (109)                |         |          |                  |                          |         |          |                  |                          |         |          |
| Pantoprazole     | –                | 11% (127)                |         |          |                  |                          |         |          |                  |                          |         |          |
| Omeprazole       | –                | 59% (670)                |         |          |                  |                          |         |          |                  |                          |         |          |
| Rabeprazole      | –                | 5% (54)                  |         |          |                  |                          |         |          |                  |                          |         |          |

Note: Categorical variables were reported in proportion (frequency), and continuous variables were reported in mean (standard deviation). Pooled t-test and Chi-square test were used to test between-group difference for continuous and categorical variables, respectively.
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CDR SOB, Clinical Dementia Rating Sum of Boxes; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; TIA, transient ischemic attack; Std. Dif., standardized difference.
FIGURE 2 Kaplan-Meier curves of (A) conversion from normal cognition to cognitive impairment (MCI or dementia) and (B) progression from MCI to dementia, between H2RA and PPI users over 5 years. The use of H2RAs was associated with earlier MCI-to-dementia progression over 5 years (adjusted HR [95% CI] = 1.402 [1.085–1.811], P = .010, Ref: PPI), whereas no association with the risk for cognitive impairment (MCI or dementia) was seen in people with normal cognition (adjusted HR [95% CI] = 0.937 [0.709–1.239], P = .648, Ref: PPI). CI, confidence interval; H2RA, histamine-2 receptor antagonist; HR, hazard ratio; MCI, mild cognitive impairment; PPI, proton pump inhibitor; Ref, reference level.

3.2 Progression to cognitive impairment or dementia in H2RA versus PPI users with normal cognition or MCI

Over 2.70 ± 2.06 years of follow-up, cognitively normal H2RA (n = 547, events = 62; 2.27 ± 1.88 years of follow-up; 0.050 events/person-year) and PPI users (n = 2237, events = 312; 2.80 ± 2.09 years of follow-up; 0.050 events/person-year) did not differ in their 5-year risk for cognitive impairment due to MCI or dementia (HR [95% confidence interval (CI)] = 0.937 [0.709–1.239], P = .648). In the MCI group, over 1.90 ± 1.76 years of follow-up, H2RA use (n = 288, events = 75; 1.48 ± 1.58 years of follow-up; 0.175 events/person-year) was associated with earlier progression from MCI to dementia within 5 years (HR [95% CI] = 1.402 [1.085–1.811], P = .010), compared to PPI use (n = 1413, events = 355; 1.99 ± 1.79 years of follow-up; 0.126 events/person-year). The Kaplan-Meier curves are shown in Figure 2. The exposure variable in the model for MCI-dementia conversion within 5 years did not violate the proportional hazards assumption (Figure S1 in supporting information).

3.3 Memory decline in H2RA versus PPI users

In mild–moderate AD (mean 1.71 ± 1.73 years of follow-up), H2RA use (n = 157; 1.53 ± 1.72 years of follow-up) was associated with faster memory decline (RR [95% CI] = 0.783 [0.671, 0.915], P = .002) than PPI use (n = 471; 1.77 ± 1.73 years of follow-up) in a mixed-effects negative binomial model. No associations with memory decline were found in MCI, or normal cognition in mixed-effects Poisson models (Figure 3).

3.4 Post hoc analyses

In post hoc analyses including all available data regardless of time from baseline (Figure S2 and S3 in supporting information), the results were similar for all outcomes. There remained a trend indicating that H2RA users exhibited earlier MCI-to-dementia progression, but the association did not reach significance (HR [95% CI] = 1.285 [0.997–1.656], P = .053; Figure S2); however, confidence in that estimate may be reduced as the proportional hazards assumption was potentially violated after 5.5 years for the exposure variable (Figure S4 in supporting information).

Excluding events within 1 year from the survival analyses did not change our conclusion (cognitively normal: HR [95% CI] = 0.913 [0.671–1.242], P = .560, n = 2733, events = 232; MCI: HR [95% CI] = 1.384 [1.046–1.832], P = .023, n = 1642, events = 371).

When 68 participants with MCI were excluded who developed dementia without an AD diagnosis, H2RA use (n = 275, events = 62) was associated with earlier progression from MCI to AD over 5 years (HR [95% CI] = 1.376 [1.038–1.824], P = .027) than PPI use (n = 1349, events = 300).
FIGURE 3  Association between delayed recall memory performance over time and the use of H2RAs or PPIs in propensity score matched samples with (A) normal cognition, (B) MCI, and (C) mild–moderate AD over 5 years. Thick lines show the predicted association over time; gray area shows 95% CIs. H2RA use was associated with faster memory decline over time in AD (RR [95% CI] = 0.783 [0.671, 0.915], P = .002, Ref: PPI), whereas no longitudinal association was seen in MCI (RR [95% CI] = 0.970 [0.940, 1.001], P = .056, Ref: PPI) or normal cognition (RR [95% CI] = 1.002 [0.988, 1.016], P = .794, Ref: PPI). AD, Alzheimer’s disease; CI, confidence interval; H2RA, histamine-2 receptor antagonist; HR, hazard ratio; MCI, mild cognitive impairment; PPI, proton pump inhibitor; Ref, reference level; RR, rate ratio

To assess how robust the HR is to unmeasured confounding, we calculated an E-value,\textsuperscript{40} which is on a risk ratio scale and denotes how strong an unmeasured confounder associated with both the exposure and outcome would need to be to explain away the observed association. The covariate-adjusted HR for MCI-to-dementia progression for H2RAs versus PPIs yielded an E-value of 1.84 (lower CI: 1.31), meaning an unmeasured confounder would require a risk ratio of 1.84 to explain away the observed association (a confounder weaker than 1.31 could not). For context, APOE ε4 had an HR of 1.56 (estimated risk ratio: 1.36) in the model. Stronger unmeasured confounders explaining away the association are unlikely because the estimate of this strong risk factor is close to the lower E-value CI.

In a post hoc model comparing antacid (negative control exposure), H2RA, and PPI users (χ² = 6.41, DF = 2, P = .041) in MCI, H2RA users showed a similar trend toward earlier progression to dementia (HR [95% CI] = 1.258 [0.912–1.737], P = .162) compared to antacid monotherapy users (n = 284, events = 89), while PPIs versus antacids did not (HR [95% CI] = 0.900 [0.703–1.152], P = .403); the HR for PPI versus H2RA users was consistent with the previous model (HR [95% CI] = 1.399 [1.084–1.805], P = .010).

4 | DISCUSSION

Among people using H2RA or PPI monotherapy, H2RA use was associated with earlier progression from MCI to dementia in people with MCI, and faster memory decline over 5 years in people with mild–moderate AD. No longitudinal relationships with cognitive decline were seen in people with normal cognition. Directly comparing patients using an H2RA versus a PPI in multiple strata, the results may be relevant to physicians and patients weighing the potential harms associated with the drug when acid suppression is required. Specifically, the evidence would be consistent with individuals with pre-existing cognitive impairment being more vulnerable to the adverse cognitive effects of H2RAs than PPIs.

The present study stratifies people into groups, with and without MCI at baseline, finding that H2RA use was associated with a 40.2% higher dementia risk, specifically for people with MCI. A previous study demonstrated a higher but insignificant risk for dementia (HR [95% CI] = 1.22 [0.85–1.72]) in H2RA users compared to PPI users.\textsuperscript{25} Another study showed that both H2RA and PPI monotherapy users had a higher risk of dementia (HR [95% CI] = 1.84 [1.49–2.20] and 1.64 [1.14–1.92], respectively) compared to users of neither.\textsuperscript{14} The present results also agree with those of a previous study comparing exposure to an H2RA versus a PPI, in which H2RA use was associated with a higher incidence of dementia within 3 years (HR [95% CI] = 1.45 [1.33–1.45]).\textsuperscript{24} Those studies did not stratify samples by the presence of MCI at baseline, which may explain why there is mixed evidence for dementia risk in PPI versus H2RA users. The present results add new evidence that dementia risk was specific to earlier progression among people with pre-existing MCI.
The present findings address further contradictions that have arisen in previous literature. Meta-analyses of dementia risk in PPI users versus non-users suggested high heterogeneity across studies, and associations between PPI use and dementia risk were not seen among studies that controlled for the use of H2RAs. Therefore, H2RA exposure may have confounded the PPI risk estimates in several previous studies. In two longitudinal studies, H2RA use was associated with higher dementia risk compared to no use, while PPI use was not. Taken with the present results, the evidence in toto suggests that H2RAs rather than PPIs might be associated with dementia risk.

H2RA versus PPI use was associated with faster decline in memory performance over time in people with mild–moderate AD, and there was a faster rate of memory decline in H2RA users with MCI, although the latter did not reach significance. A cross-sectional study demonstrated that H2RA rather than PPI use was associated with worse performance in several cognitive domains. A longitudinal analysis showed that neither PPI nor H2RA use was associated with memory decline in cognitively normal people. Those findings are consistent with the present evidence, but we further highlight that H2RAs may be more detrimental than PPIs to certain aspects of cognition, specifically in people with pre-existing cognitive impairment, having marked effects on memory performance among people with clinical AD.

A conflicting study found that PPI users had greater odds of reporting memory impairment compared to H2RA users in the United States Food and Drug Administration (FDA) adverse event reporting system from 2004 to 2018. Two case-control studies reported no association between use of an H2RA and likelihood of dementia. Those contradictory results were mainly from cross-sectional or case-control studies, whereas the present study examined cognitive decline prospectively, and it is the first report to show a longitudinal association between faster decline in memory performance and H2RA versus PPI use in people with clinically diagnosed AD.

The biological plausibility of the present findings is supported by a potential dose-response relationship between H2RA use and dementia risk observed in several studies, while no study has found a substantial dose-response relationship for PPI use. H2RAs have been suggested to be anticholinergic in vitro, and they are included in the anticholinergic cognitive burden scale. Recently, PPIs were also found to have anticholinergic potential. Anticholinergic burden may explain the association between H2RA use and cognitive decline particularly among those with loss of cholinergic synapses in MCI and AD. Also, PPIs and H2RAs were suggested to have differential effects on gut microbiome, which might be explored as a mediator. As a limitation, data on the microbiome and H. pylori infection were not available in the dataset precluding subgroup analyses for different indications.

Both H2RAs and PPIs have been linked to vitamin B12 deficiency, which may lead to cognitive decline. In addition, PPIs promoted AD pathology in preclinical studies, and a randomized controlled trial of healthy young volunteers found that PPI use could impair cognition, suggesting that the PPIs are not likely without potential harm. However, clinically when potent acid suppression is necessary, a choice must be made between the classes, which should be informed by clinical evidence comparing the two options. The present findings provide evidence that the PPIs may be less detrimental than H2RAs in the context of cognitive impairment; however, randomized controlled trial data comparing them directly at different doses in specific populations who require acid suppression are lacking.

There were fewer long-term H2RA users than long-term PPI users in the current analysis, suggesting that using only data within 5 years might be more reliable than using data across all available time points when trying to infer effects of the drug exposure. Switching from an H2RA to a PPI was more frequent than vice versa; 50 out of 288 (17%) baseline H2RA users switched to a PPI whereas 86 out of 1413 (6%) PPI users switched to an H2RA within 5 years. Switchers were censored to avoid misattribution of harms. Because this censoring may have been informative, the true harms of H2RAs might have been greater than those estimated; however, associations were still identified.

As another limitation, variables such as prescription versus over-the-counter H2RAs/PPIs, disease severity, ulcer diagnosis, and socioeconomic status were not available, which might introduce residual confounding, as H2RA monotherapy users might represent those with milder gastroesophageal reflux disease symptoms or those with poorer health care access. Nonetheless, analyses with the E-value and negative control exposure implied that the association was likely robust to such unmeasured confounders. Drug exposure prior to entry into the database was not available, and reporting of over-the-counter drugs was optional, which could have introduced some misclassification bias. Dose, duration, and frequency of drug use were not available; thus, cumulative effects and potential dose-response relationships could not be well studied. Also, interval censoring led to loss of information of drug use and cognitive status between visits; however, the identification of MCI or dementia based on predefined criteria at each visit offered higher confidence in classification of the time of the outcome compared to community samples. Last, the sample size was insufficient to explore differences associated with individual drugs within the classes, risks of specific types of dementia, or associations with cognitive decline in people with cognitive impairment not due to MCI or AD; however, a post hoc analysis suggested that the association was consistent among those who converted specifically to AD dementia.

5 | CONCLUSION

No differential risk for incident clinical cognitive impairment or memory decline was seen between H2RA and PPI use in older people with normal cognition; however, among people with MCI, H2RA users had earlier progression to dementia over 5 years compared to PPI users. Also, H2RA use was associated with faster memory decline in people with mild–moderate AD, but not in people with normal cognition. The current study refutes previous evidence that PPI use is associated with a higher dementia risk, and it highlights that people with MCI or AD who require an acid suppressant may be more vulnerable to cognitive harms related to H2RA exposure than to exposure to a PPI.
ACKNOWLEDGMENTS
The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADRCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P50 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P50 AG008051 (PI Thomas Wisniewski, MD), P50 AG013854 (PI Robert Vassar, PhD), P50 AG008017 (PI Jeffrey Kaye, MD), P50 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P50 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P50 AG035982 (PI Russell Swardfager, MD, PhD), P30 AG028383 (PI Linda Van Eldik, PhD), P50 AG035760 (PI Henry Paulson, MD, PhD), P50 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD), Walter Swardfager gratefully acknowledges that this research was financially supported by the Canadian Institute of Health Research (CIHR), Grant/Award Number: PJT-159711; The Natural Sciences and Engineering Research Council of Canada (NSERC), Grant/Award Number: RGPIN-2017-06962; Alzheimer’s Association & Brain Canada, Grant/Award Number: AARG501466; (NSERC), Grant/Award Number: RGPIN-2017-06962; Alzheimer’s Association & Brain Canada, Grant/Award Number: AARG501466; Weston Brain Institute & Alzheimer’s Research UK, Alzheimer’s Association and Michael J. Fox Foundation, Grant/Award Number: BAND3.

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

ORCID
Walter Swardfager https://orcid.org/0000-0002-0030-8908

REFERENCES
1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3.
2. Tai SY, Chien C-Y, Wu D-C, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS One. 2017;12:e0171006.
3. Zhang Y, Liang M, Sun C, et al. Proton pump inhibitor use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol. 2020;76:139-147.
4. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419-428.
5. Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacopeiendiological claims data analysis. JAMA Neurol. 2016;73:410-416.
6. Welu J, Metzger J, Bebensee S, Ahrendt A, Vasek M. Proton pump inhibitor use and risk of dementia in the veteran population. Fed Pract. 2019;36:527-31.
7. Desai M, Ntalapati V, Srinivasan S, et al. Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Dis Esophagus. 2020;33.
8. Taihape H, Tolppanen A-M, Tähtinen M, Tanskanen A, Tähtinen J, Haritikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol. 2017;112:1802-1808.
9. Booker A, Jacob LEC, Rapp M, Bohlsen K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatrics. 2016;28:1059-1065.
10. Herridge H, Shiva A, Lanthier J, et al. Reduced prevalence of AD with NSAID but not H2 receptor antagonists. Neurology. 2000;54:2066-2071.
11. Torres-Bondia F, Daktzerzada F, Galván L, et al. Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias. Sci Rep. 2020;10:21046.
12. Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc. 2007;55:1248-1253.
13. Hwang IC, Chang J, Park SM. A nationwide population-based cohort study of dementia risk among acid suppressant users. Am J Geriatr Psychiatry. 2018;26:1175-1183.
14. Chen L-Y, Lin H-J, Wu W-T, et al. Clinical use of acid suppressants and risk of dementia in the elderly: a pharmaco-epidemiological cohort study. Int J Environ Res Public Health. 2020;17:8271.
15. Lochhead P, Hagan K, Joshi AD, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153:971-979.
16. Impfeld P, Bodmer M, Jick SS, Meier CR. Proton pump inhibitor use and risk of developing Alzheimer’s disease or vascular dementia: a case-control analysis. Drug Saf. 2018;41:1387-1396.
17. Zhang Y, Zhan J, Bao Q, Lu J, Tan L. Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: a meta-analysis study. Med Hypotheses. 2020;144:109989.
18. Gray SL, Walker R, Dublin S, et al. Histamine-2 receptor antagonist use and incident dementia in an older cohort. J Am Geriatr Soc. 2011;59:251-257.
19. Anthony JC, Breitner JCS, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists. Neurology. 2000;54:2066-2071.
20. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JCS. Reduced incidence of AD with NSAID but not H2 receptor antagonists. Neurology. 2002;59:880-886.
21. Makunts T, Alpatty S, Lee KC, Atayee RS, Abaygan R. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Sci Rep. 2019;9:17280.
22. Nevado-Holgado AJ, Kim C-H, Winchester L, Gallacher J, Lovestone S. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open. 2016;6:e012177.
23. Collin BG, Raju D, Altmann J, Katsikas S. The effects of proton pump inhibitors on neuropsychological functioning. Appl Neuropsychol Adult. 2021:1-10. <bib>
24. Park S-K, Nam JH, Lee H, Chung H, Lee E-K, Shin J-Y. Beyond uncertainty: negative findings for the association between the use of proton pump inhibitors and risk of dementia. J Gastroenterol Hepatol. 2019;34:2135-2143.
25. Wu C-L, Lei W-Y, Wang J-S, Lin C-E, Chen C-L, Wen S-H. Acid suppressants use and the risk of dementia: a population-based propensity score-matched cohort study. PLoS One. 2020;15:e0242975.
26. Tune L, Carr S, Hoag ECT. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992;149:1393-1394.
27. Kumar R, Kumar A, Nordberg A, Långström B, Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors...
of the acetylcholine biosynthesizing enzyme—a plausible missing link for their association with incidence of dementia. Alzheimer’s Dement. 2020;16:1031-1042.

28. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Dist. 2006;20:210-216.

29. Besser L, Kukull W, Knopman DS, et al. Version 3 of the National Alzheimer’s Coordinating Center’s uniform data set. Alzheimer Dis Assoc Dist. 2018;32:351-358.

30. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.

31. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263-269.

32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939-944.

33. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.

34. Chelune GJ, Bornstein RA, Prifitera A. The Wechsler memory scale—revised. Adv Psychol Assess. 1990;2:65-99.

35. R Core Team. R: a language and environment for statistical computing. 2018.

36. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag; 2016.

37. Therneau TM. A package for survival analysis in R. 2021.

38. Ho DE, Imai K, King G, Stuart EA. {MatchIt}: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1-28.

39. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using {lme4}. J Stat Softw. 2015;67:1-48.

40. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268-274.

41. Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;65:1969-1974.

42. Huang S-T, Tseng L-Y, Chen L-K, Peng L-N, Hsiao F-Y. Does long-term proton pump inhibitor use increase risk of dementia? Not really! Results of the group-based trajectory analysis. Clin Pharmacol Ther. 2019;106:616-622.

43. Cooksey R, Kennedy J, Dennis MS, et al. Proton pump inhibitors and dementia risk: evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One. 2020;15:e0237676.

44. Gray SL, Walker RL, Dublin S, et al. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc. 2018;66:247-253.

45. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311-320.

46. Lin Y-T, Lin T-Y, Hung S-C, et al. Anti-acid drug treatment induces changes in the gut microbiome composition of hemodialysis patients. Microorganisms. 2021;9:286.

47. Shindler-Itskovitch T, Ravona-Springer R, Leibovitz A, Muesen K. A systematic review and meta-analysis of the association between helicobacterpylori infection and dementia. J Alzheimers Dis. 2016;52:1431-1442.

48. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435-2442.

49. Ortiz-Guerrero G, Amador-Muñoz D, Calderón-Ospina CA, López-Fuentes D, Nava Mesa MO. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast. 2018:2018:5257285.

50. Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG, Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015;7:79.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Wu C-Y, Xiong LY, Ouk M, et al. Gastric acid suppressants and cognitive decline in people with or without cognitive impairment. Alzheimer’s Dement. 2022;8:e12243. https://doi.org/10.1002/trc2.12243